Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 823-828, 2007. First published March 15, 2007; 10.1373/clinchem.2006.081539
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 081539.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2006.081539v1
53/5/823    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, H.-K.
Right arrow Articles by Yeo, K.-T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, H.-K.
Right arrow Articles by Yeo, K.-T. J.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 2007;53:823-828.)
© 2007 American Association for Clinical Chemistry, Inc.

Molecular Diagnostics and Genetics

Validation of a CYP2D6 Genotyping Panel on the NanoChip Molecular Biology Workstation

Hong-Kee Lee1, Lionel D. Lewis2, Gregory J. Tsongalis1, Bernard C. Schur3, Paul J. Jannetto3, Steven H. Wong3 and Kiang-Teck J. Yeo1,a

1 Department of Pathology, and 2 Section of Clinical Pharmacology, Department of Medicine, Dartmouth Medical School and Dartmouth-Hitchcock Medical Center, Lebanon, NH.
3 Department of Pathology, Medical College of Wisconsin, Milwaukee, WI.

aAddress correspondence to this author at: Department of Pathology, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756. Fax 603-650-8590; e-mail jyeo{at}dartmouth.edu.

Background: CYP2D6 is a highly polymorphic phase I enzyme that metabolizes 20%–25% of clinically used drugs. The objective of this study was to validate a CYP2D6 genotyping assay with the NanoChip® Molecular Biology Workstation.

Methods: We genotyped 200 anonymized human DNA samples with the Pyrosequencing® platform at the Medical College of Wisconsin and with the NanoChip platform at Dartmouth Medical School. We compared CYP2D6 genotypes and resolved samples with genotypic discrepancies with the Jurilab CYP2D6 duplication/deletion assay or with traditional DNA sequencing. The Jurilab assay is a long-range PCR assay used to evaluate sequence structures 3' of the CYP2D7 and CYP2D6 coding regions. For the NanoChip platform, we performed multipad addressing and duplicate runs to test the intra- and intercartridge precision, within- and between-run precision, and reproducibility of the defined genotypes.

Results: We used both platforms to genotype all 200 DNA samples for CYP2D6*3, *4, *5, *6, *7, *8, and gene duplication. The 2 methods showed 99.4% concordance in the genotyping results; we found only 8 discrepant genotypes among 1400 DNA analyses. Confirmatory molecular analysis of the discrepant genotypes revealed that the NanoChip assay showed better agreement. The imprecision of the NanoChip method (CV) was 8.9%–17.7%.

Conclusions: This validation study of the NanoChip electronic microarray–based CYP2D6 genotyping assay revealed a CV <20% and good concordance with the Pyrosequencing method and a confirmatory sequencing method.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.